Treatment and Management of Dementia Due to Alzheimer’s Disease

  • Jennifer Rose V. MolanoEmail author
  • Robin Bratt
  • Rhonna Shatz
Dementia (E McDade, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Dementia

Opinion statement

Alzheimer’s disease (AD) is a progressive neurological disorder typically associated with episodic memory loss as the initial symptom, but individuals <65 years old may present with executive dysfunction, word finding difficulties, or visual processing deficits. In those with AD, curative treatments are not available, but there are interventions which may modify disease course, symptom appearance and severity, enhance quality of life for patient and caregivers, and maintain safety. Both pharmacological and non-pharmacological interventions are important.


Alzheimer’s disease Treatment Management Dementia 


Compliance with Ethics Guidelines

Conflict of Interest

Jennifer Rose V. Molano, Robin Bratt, and Rhonna Shatz declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    McKhann GM et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimer’s Dement. 2011;7(3):263–9.CrossRefGoogle Scholar
  2. 2.••
    Odenheimer G et al. Quality improvement in neurology: dementia management quality measures. Neurology. 2013;81:1545–9. Brief overview of the dementia management quality measures with a link to the Physician Consortium for Performance Improvement Website.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Barnard ND et al. Dietary and lifestyle guidelines for the prevention of Alzheimer’s disease. Neurobiol Aging. 2014;35:S74–8.PubMedCrossRefGoogle Scholar
  4. 4.•
    Ngandu T et al. A 2 year multi-domain intervention of diet, exercise, cognitive training and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER); a randomized controlled trial. Lancet. 2015. doi: 10.1016/S0140-6736(15)60461-5. Large, randomized controlled trial showing the importance of lifestyle modification in modifying cognitive decline.PubMedGoogle Scholar
  5. 5.
    Singh B et al. Association of Mediterranean diet with mild cognitive impairment and Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;39(2):271–82.PubMedCentralPubMedGoogle Scholar
  6. 6.
    van de Rest O et al. Dietary patterns, cognitive decline, and dementia: a systematic review. Adv Nutri. 2015. doi: 10.3945/an.114.007617.Google Scholar
  7. 7.
    Swaminathan A, Jicha GA. Nutrition and prevention of Alzheimer’s disease. Front Aging Neurosci. 2014. doi: 10.3389/fnagi.2014.00282.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Ripjima A, Meulenbroek O, Olde Rikkert MGM. Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer’s disease: a systematic review of randomized controlled trials. Ageing Res Rev. 2014;16:105–12.CrossRefGoogle Scholar
  9. 9.
    Forbes D et al. Exercise programs for people with dementia. Cochrane Database Syst Rev. 2013;12, CD006489.PubMedGoogle Scholar
  10. 10.
    Bossers WJ et al. A 9-week aerobic and strength training program improves cognitive and motor function in patients with dementia: a randomized, controlled trial. Am J Geriatr Psychiatry. 2015. doi: 10.1016/j.jagp.2014.12.191.PubMedGoogle Scholar
  11. 11.
    Brown D et al. Development of an exercise intervention to improve cognition in people with mild to moderate dementia: dementia and Physical Activity (DAPA) trial, registration ISRCTN32612072. Physiotherapy. 2015. doi: 10.1016/ Scholar
  12. 12.
    Chokroverty S. Sleep and neurodegenerative diseases. Semin Neurol. 2009;29(4):446–67.PubMedCrossRefGoogle Scholar
  13. 13.
    Kondratova AA et al. The circadian clock and pathology of the aging brain. Nat Rev Neurosci. 2012;13(5):325–35.PubMedCentralPubMedGoogle Scholar
  14. 14.
    McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in Alzheimer’s disease. Cochrane Database Syst Rev. 2014;3, CD009178.PubMedGoogle Scholar
  15. 15.
    Xu J et al. Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2015. doi: 10.1177/1533317514568005.Google Scholar
  16. 16.
    McCurry SM et al. Increasing walking and bright light exposure to improve sleep in community-dwelling persons with Alzheimer’s disease: results of a randomized, controlled trial. J Am Geriatr Soc. 2011;59:1393–402.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Molano J, Vaughn BV. Approach to insomnia in patients with dementia. Neurol Clin Pract. 2014;4(1):7–15.CrossRefGoogle Scholar
  18. 18.
    Ruthirakuhan M et al. Use of physical and intellectual activities and socialization in the management of cognitive decline of aging and dementia: a review. J Aging Res. 2012. doi: 10.3233/JAD-130866.PubMedCentralPubMedGoogle Scholar
  19. 19.
    Hyde C et al. Evolution of the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer’s disease: systematic review and economic model. Age and Aging. 2013;42:14–20.CrossRefGoogle Scholar
  20. 20.
    Tan CC et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;41(2):615–31. doi: 10.3233/JAD-132690.PubMedGoogle Scholar
  21. 21.
    Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1, CD005593.PubMedGoogle Scholar
  22. 22.
    Massoud F, Gauthier S. Update on the pharmacological treatment of Alzheimer’s disease. Curr Neuropharmacol. 2010;8(1):69–80.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Di Oliviera FF et al. Pharmacological modulation of cognitive and behavioral symptoms in patients with Alzheimer’s disease. J Neuro Sci. 2014;336(1–2):103–8.CrossRefGoogle Scholar
  24. 24.
    Kavanaugh S, VanBaelen B, Schӓuble B. Long term effects of galantamine on cognitive function in Alzheimer’s disease: a large scale international retrospective study. J Alzheimer’s Disord. 2011;27:521–30.Google Scholar
  25. 25.
    Lyle S et al. Treatment of whole population sample of Alzheimer’s disease with donepezil over a 4 year period: lessons learned. Dement Geriatr Cogn Disord. 2008;25:226–31.PubMedCrossRefGoogle Scholar
  26. 26.
    Di Santo SG et al. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer’s disease. J Alzheimers Dis. 2013;35(2):349–61. doi: 10.3233/JAD-122140.PubMedGoogle Scholar
  27. 27.
    Cummings JL et al. A practical algorithm for managing Alzheimer’s disease: what, when and why? Ann Clin Transl Neurol. 2015;2(3):307–23.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.•
    Massoud F, Desmarais JE, Gauthier S. Switching cholinesterase inhibitors in older adults with dementia. Int Psychogeriatri. 2011;23(3):372–8. Good review of studies that have investigated the switch of cholinesterase inhibitors in AD, with a practical approach in addressing intolerance and lack of efficacy with these medications.CrossRefGoogle Scholar
  29. 29.
    Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from multidisciplinary expert panel. J Am Geriatr Soc. 2014;62:762–9.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Gitlin LN, Kales HC, Lyketsos CG. Managing behavioral symptoms in dementia using nonpharmacologic approaches: an overview. JAMA. 2012;308(19):2020–9.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Smits CH et al. Effects of combined intervention programs for people with dementia living at home and their caregivers: a systematic review. Int Geriatr Psychiatry. 2007;22(12):1181–93.CrossRefGoogle Scholar
  32. 32.
    Rosalynn Carter Institute for Caregiving. What Makes A Caregiver Program Effective? 2012.
  33. 33.
    Gitlin LN et al. Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention. J Am Geriatr Soc. 2010;58(8):1465–74.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.••
    Kales HC and Gitlin LN. Assessment and management of behavioral and psychological symptoms of dementia. BMJ 2015;5:350:h369 doi: 10.1136/bmjJ369. Excellent summary of NPS, factors contributing to symptoms, evidence for non-pharmacological and pharmacological interventions, theoretical framework and strategies for assessment, evaluations and management strategies for the clinician, initiating treatment plan and suggestions for collaboration and referral. Comprehensive reference list includes many historically and currently relevant articles on which knowledge is being built.
  35. 35.
    Adelman RD et al. Care giver burden: a clinical review. JAMA. 2014;311(10):1052–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Cummings JL et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–14.PubMedCrossRefGoogle Scholar
  37. 37.
    Steinberg M et al. Point and 5 year period prevalence of neuropsychiatric symptoms in dementia: the Cache county study. Int J Geriatr Psychiatry. 2008;23:170–7.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Thyrian JR et al. Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care: results of the DelpHi Study. J Alzheimers Dis. 2015. doi: 10.3233/JAD-143114.Google Scholar
  39. 39.
    Madhusoodanan S, Ting MB. Pharmacological management of behavior symptoms associated with dementia. World J Psychiatry. 2014;4(4):72–9.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Corbett A, Smith J, Creese B, Ballard C. Treatment of behavioral and psychological symptoms of Alzheimer’s disease. Curr Treat Options Neurol. 2012;14:113–25.PubMedCrossRefGoogle Scholar
  41. 41.
    Tagariello P, Girardi P, Amore M. Depression and apathy in dementia: same syndrome or different constructs: a critical review. Arch Gerontol Geriatr. 2009;49(2):246–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Berman K, Brodaty H, Withall A, Seeher K. Pharmacologic treatment of apathy in dementia. Am J Geriatr Psychiatr. 2012;20(2):104–22.CrossRefGoogle Scholar
  43. 43.
    Rea R et al. Review article: apathy in Alzheimer’s disease: any effective treatment? Sci World J. 2014. doi: 10.1155/2014/421385.Google Scholar
  44. 44.
    Enache D, Winblad B, Aarsland D. Depression in dementia: epidemiology, mechanisms, and treatment. Curr Opin Psychiatry. 2011;24(6):461–7.PubMedGoogle Scholar
  45. 45.
    Ortega V et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2014;1, CD009125.Google Scholar
  46. 46.
    Leong C. Antidepressants for depression in patients with dementia: a review of the literature. Consult Pharm. 2014;29(4):254–63.PubMedCrossRefGoogle Scholar
  47. 47.
    Federal Drug Administration. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. 2012.
  48. 48.
    Nassisi D et al. The evaluation and management of the acutely agitated patient. Mt Sinai J Med. 2006;73(7):976–84.PubMedGoogle Scholar
  49. 49.
    Trihn NH et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer’s disease; a meta-analysis. JAMA. 2003;289(2):210–6.CrossRefGoogle Scholar
  50. 50.
    Seitz DP et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;2, CD008819.Google Scholar
  51. 51.
    Pollock BG et al. A double blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatr. 2007;15:942–52.CrossRefGoogle Scholar
  52. 52.
    Porsteinsson AP et al. CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682–91.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Desai AK, Grossberg GT. Buspirone in Alzheimer’s disease. Expert Rev Neurother. 2003;3(1):19–28.PubMedCrossRefGoogle Scholar
  54. 54.
    Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev. 2009;3, CD003945.PubMedGoogle Scholar
  55. 55.
    Amann B et al. Anticonvulsants in the treatment of aggression in the demented elderly. Clin Pract Epidemiol Ment Health. 2009;5:14.PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Seitz DP et al. Pharmacologic treatments for neuropsychiatric symptoms of dementia in long term care: a systematic review. Int Psychogenics. 2013;25(2):185–203.CrossRefGoogle Scholar
  57. 57.
    Wilcock GK et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of three studies. J Clin Psychiatry. 2008;69(3):341–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Schneider LS, Tariot PN, Dagerman KS, Davis SM. Effectiveness of atypical antipsychotics drugs in patients with Alzheimer’s disease. NEJM. 2006;355(15):1525–38.PubMedCrossRefGoogle Scholar
  59. 59.
    Wang PS et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335–41.PubMedCrossRefGoogle Scholar
  60. 60.
    Maust DT et al. Antipsychotics, other psychotropics, and risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438–45.PubMedCrossRefGoogle Scholar
  61. 61.
    Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1, CD003476.PubMedGoogle Scholar
  62. 62.•
    Vigen CLP et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. Am J Psychiatr. 2011;168:831–9. Describes risk of worsening cognitive impairment with atypical antipsychotics.PubMedCentralPubMedCrossRefGoogle Scholar
  63. 63.
    Maher AR et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off label uses in adults: a systemic review and meta-analysis. J Am Med Assoc. 2011;306(12):1359–69.CrossRefGoogle Scholar
  64. 64.
    Corbett A, Burns A, Ballard C. Don’t use antipsychotics routinely to treat agitation and aggression in people with dementia. BMJ. 2014;349:g6420. doi: 10.1136/bmj.g6420.PubMedCrossRefGoogle Scholar
  65. 65.••
    Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo controlled trials. JAMA. 2005;294:1934–43. Study that initiated the FDA warning black box warning for atypical antipsychotics.PubMedCrossRefGoogle Scholar
  66. 66.
    Ma H et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimer ’s Dis. 2014;42(3):915–37.Google Scholar
  67. 67.
    Ballard C et al. The dementia antipsychotic withdrawal trial (DART-AD): long term follow up of a randomized placebo-controlled trail. Lancet Neurol. 2009;8(2):151–7.PubMedCrossRefGoogle Scholar
  68. 68.
    Declerq T. Withdrawal versus continuation of chronic antipsychotics drugs for behavioral and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2002; 3. CD007726.Google Scholar
  69. 69.
    De Deyn PP et al. Aripiprazole in the treatment of Alzheimer’s disease. Expert Opin Pharmacother. 2013;14(4):459–74.PubMedCrossRefGoogle Scholar
  70. 70.
    Mintzer JE et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007;15(11):918–31.PubMedCrossRefGoogle Scholar
  71. 71.
    Anand R et al. Therapeutics of Alzheimer’s disease: past, present, and future. Neuropharmacology. 2014;76:27–50.PubMedCrossRefGoogle Scholar
  72. 72.
    Sperling RA et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–92.PubMedCentralPubMedCrossRefGoogle Scholar
  73. 73.
    Wang LY et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatr. 2009;17:744–51.CrossRefGoogle Scholar
  74. 74.
    Thurman DJ et al. Practice parameter: assessing patients in a neurology practice for risk of falls (an evidence-based review). Neurology. 2008;70:473–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Iverson DJ et al. Practice parameter update: evaluation and management of driving risk in dementia. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74:1316–24.PubMedCentralPubMedCrossRefGoogle Scholar
  76. 76.
    Arlt S et al. Adherence to medication in patients with dementia. Drugs Aging. 2008;25(12):1033–47.PubMedCrossRefGoogle Scholar
  77. 77.
    Morris JC. The clinical dementia rating (CDR): current vision and scoring rules. Neurology. 1993;43:2412–4.PubMedCrossRefGoogle Scholar
  78. 78.
    Chiachiaro J, Arnold RM, White DB. Reengineering advance care planning to create scalable, patient- and family-centered interventions. JAMA. 2015;313(11):1103–4.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Jennifer Rose V. Molano
    • 1
    Email author
  • Robin Bratt
    • 1
  • Rhonna Shatz
    • 1
  1. 1.Department of Neurology and Rehabilitation MedicineThe University of Cincinnati College of MedicineCincinnatiUSA

Personalised recommendations